Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc

Journal of Clinical Virology

Volumn 55, Issue 2, 2012, Pages 134-139

  McNicholas, Paul ^a   Vilchez, Regis A ^a   Greaves, Wayne ^a   Kumar, Sushma ^a   Onyebuchi, Chinyere ^a   Black, Todd ^a   Strizki, Julie M ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

CCR5; CXCR4; HIV resistance; HIV tropism; Vicriviroc

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; INTEGRASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VICRIVIROC;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CLONE; CONTROLLED STUDY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; MUTATION; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TREATMENT DURATION; TREATMENT FAILURE; VIRAL TROPISM; VIRUS DETECTION; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; PIPERAZINES; PYRIMIDINES; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE; VIRAL TROPISM;

EID: 84865163658     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2012.06.021     Document Type: Article

References (19)

1. Dorr P., Westby M., Dobbs S., Griffin P., Irvine B., Macartney M., et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005, 49:4721-4732.
2. Kuhmann S.E., Pugach P., Kunstman K.J., Taylor J., Stanfield R.L., Snyder A., et al. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol 2004, 78:2790-2807.
3. Strizki J.M., Tremblay C., Xu S., Wojcik L., Wagner N., Gonsiorek W., et al. Discovery and characterization of vicriviroc (SCH417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005, 49:4911-4919.
4. Westby M., Smith-Burchnell C., Mori J., Lewis M., Mosley M., Stockdale M., et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007, 81:2359-2371.
5. McNicholas P., Wei Y., Whitcomb J., Greaves W., Black T.A., Tremblay C.L., et al. Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial. J Infect Dis 2010, 201:1470-1480.
6. McNicholas P.M., Mann P.A., Wojcik L., Phd P.Q., Lee E., McCarthy M., et al. Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1). J Acquir Immune Defic Syndr 2011, 56:222-229.
7. Ogert R.A., Wojcik L., Buontempo C., Ba L., Buontempo P., Ralston R., et al. Mapping resistance to the CCR5 coreceptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 2008, 373:387-399.
8. Pugach P., Marozsan A.J., Ketas T.J., Landes E.L., Moore J.P., Kuhmann S.E. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007, 361:212-228.
9. Ogert R.A., Hou Y., Ba L., Wojcik L., Qiu P., Murgolo N., et al. Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5. Virology 2010, 400:145-155.
10. Gulick R.M., Su Z., Flexner C., Hughes M.D., Skolnik P.R., Wilkin T.J., et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007, 196:304-312.
11. Suleiman J., Zingman B.S., Diaz R.S., Madruga J.V., DeJesus E., Slim J., et al. Vicriviroc in combination therapy with an optimized regimen for treatment experienced subjects: 48 week results of the VICTOR-E1 phase 2 trial. J Infect Dis 2010, 201:590-599.
12. Caseiro M.M., Nelson M., Diaz R.S., Gathe J., De Andrade Neto J.L., Slim J., et al. Vicriviroc plus optimized background therapy for treatment-experienced patients with CCR5 HIV-1 infection: final results from two randomized trials. J Infect 2012, 10.1016/j.jinf.2012.05.008.
13. Hammer S.M., Saag M.S., Schechter M., Montaner J.S., Schooley R.T., Jacobsen D.M., et al. Treatment for adult HIV infection. JAMA 2006, 296:827-843.
14. Whitcomb J.M., Huang W., Fransen S., Limoli K., Toma J., Wrin T., et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007, 51:566-575.
15. Reeves J.D., Coakley E., Petropoulos C.J., Whitcomb J.M. An enhanced-sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. J Viral Entry 2009, 3:94-102.
16. Fätkenheuer G., Nelson M., Lazzarin A., Konourina I., Hoepelman A.I., Lampiris H., et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008, 359:1442-1455.
17. Gulick R.M., Lalezari J., Goodrich J., Clumeck N., DeJesus E., Horban A., et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008, 359:1429-1441.
18. Mori J., Mosley M., Lewis M., Simpson P., Toma J., Huang W., et al. Characterization of maraviroc resistance in patients failing treatment with CCR5-tropic virus in MOTIVATE 1 and MOTIVATE 2. Antiviral Ther 2007, 12:S12.
19. Berro R., Klasse P.J., Moore J.P., Sanders R.W. V3 determinants of HIV-1 escape from the CCR5 inhibitors maraviroc and vicriviroc. Virology 2012, 427:158-165.